ViroCell Biologics
Chemicals & Related Products · United Kingdom · 51-200 Employees
View Company Info for Free
Overview
Headquarters
12-18 Theobalds Rd, London, Greater Lond...Phone Number
+44 2045585438Website
www.virocell.comRevenue
$14.8 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About ViroCell Biologics
ViroCell Biologics is an innovation-driven Contract Development and Manufacturing Organization (CDMO) specializing in the design and GMP manufacture of lentiviral and retroviral vectors. Their services are aimed at enabling novel cell and gene therapies to progress into clinical trials. With over 25 years of experience, ViroCell focuses on optimizing vector design and improving manufacturing processes to enhance therapy development. They cater to innovators in the biotechnology and pharmaceutical sectors looking to transition their therapies from lab to clinical application.Explore more
ViroCell Biologics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ViroCell Biologics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if ViroCell Biologics has recently received funding, and reach out quickly before it becomes old news!
Check out if ViroCell Biologics is spiking on competitors!
Click to see if ViroCell Biologics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at ViroCell Biologics
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once ViroCell Biologics has new funding data
Earning: See what the market has to say on ViroCell Biologics recently announced quarterly report
ViroCell Biologics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when ViroCell Biologics launches new products
Recommended Actions
Find VP level buyers at ViroCell Biologics
Find 2 more new buyers
Company Profile Activity
Activity Insights
ViroCell Biologics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ViroCell Biologics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ViroCell Biologics.
ViroCell Biologics Tech Stack
A closer look at the technologies used by ViroCell Biologics
Most Recent Scoops
Project
, according to a front-line source in operations management, is planning to begin initiatives related to communication systems within three to six months. The organization is currently evaluating Google Keep. These efforts are focused on speeding up information flow and improving organizational decision-making and coordination.
Software, Unified Communications, Strategic Communications, Communications, Operations
Pain Point
Project
, according to a front-line source in operations management, is experiencing challenges related to project, portfolio, and program management software.
Pain Point, Enterprise Software, Software, Workforce Management, Operations
Pain Point
, according to a front-line source in operations management, is experiencing challenges related to business process management (BPM).
Pain Point, Analytics & Insights, Workforce Management, Corporate Strategy, Operations
Project
, according to a front-line source in operations management, is planning to begin initiatives related to capacity planning within three months. The organization is currently evaluating Global Shop Solutions, MindBridge, and NetSuite. These efforts are focused on improving workload distribution, allowing peak-period scaling, and reducing bottlenecks.
Capacity Planning, Facilities Management, Operations
Project
Document Management, Software, Operations
ViroCell Biologics News & Media
ViroCell Biologics Appoints Viral Vector Expert as Special Advisor
LONDON & NEW YORK--(BUSINESS WIRE)--ViroCell Biologics (“ViroCell” or the “Company”), a cell and gene therapy (“CGT”) contract development and manufacturing organization (“CDMO”) specializing in GMP viral vector manufacturing for clinical trials, announces the appointment of James Miskin as a Special Advisor. James will leverage expertise gained from a 25-year career in CGT to support ViroCell’s continued growth and technical development. James spent over 23 years at Oxford Biomedica (OXB), witViroCell Biologics Expands U.S. Business Development Team With Two New Appointments
LONDON & NEW YORK--(BUSINESS WIRE)--ViroCell Biologics (“ViroCell” or the “Company”), a cell and gene therapy (“CGT”) contract development and manufacturing organization (“CDMO”) specializing in GMP viral vector manufacturing for clinical trials, announces the expansion of the Company’s U.S. business development team with the appointments of Meredith Brown, as Senior Director, and Elaine Rihn as Director of Business Development. Both join from Lonza Inc., a global CDMO, where their roles focuseViroCell Biologics to Host Panel Event at 2024 Cell & Gene Meeting on the Mesa
LONDON & NEW YORK--(BUSINESS WIRE)--ViroCell Biologics (“ViroCell” or the “Company”), a cell and gene therapy (“CGT”) Contract Development and Manufacturing Organization (“CDMO”) specializing in GMP viral vector manufacturing for clinical trials, announces that Farzin Farzaneh, PhD, Co-Founder and Chief Scientific Officer of ViroCell Biologics, will be hosting a panel event on Synthetic Biology at the annual Cell & Gene Therapy Meeting on the Mesa, to be held on 7-9 October 2024 in Phoenix,ViroCell Biologics Completes Oversubscribed Financing
LONDON & NEW YORK--(BUSINESS WIRE)--ViroCell Biologics (“ViroCell” or the “Company”), a cell and gene therapy (“CGT”) contract development and manufacturing organization (“CDMO”) specializing in GMP viral vector manufacturing for clinical trials, announces the completion of an oversubscribed convertible note offering. The oversubscription was led by new investor First Light Asset Management LLC, joining existing investors including Sartorius Stedim Biotech S.A. and Dorset Opportunity Fund LP. P
Read more news
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ViroCell Biologics
Sign Up For FreeTo access detailed company insights
ViroCell Biologics is an innovation-driven Contract Development and Manufacturing Organization (CDMO) specializing in the design and GMP manufacture of lentiviral and retroviral vectors. Their services are aimed at enabling novel cell and gene therapies to progress into clinical trials. With over 25 years of experience, ViroCell focuses on optimizi... Read More
